盐酸阿比多尔治疗中国人群呼吸道病毒感染有效性和安全性的系统评价  

Efficacy and safety of arbidol hydrochloride for respiratory viral infection in Chinese population:a systematic review

作　　者：司霞[1] 宋荣景 封宇飞 黄琳[1] SI Xia;SONG Rong-jing;FENG Yu-fei;HUANG Lin(Department of Pharmacy,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院药剂科,北京100044

出　　处：《临床药物治疗杂志》2020年第3期31-37,共7页Clinical Medication Journal

摘　　要：目的系统评价盐酸阿比多尔治疗中国人群呼吸道病毒感染的疗效与安全性。方法计算机检索Embase、PubMed、Cochrane Library、中国知网、万方数据库及维普数据库中已发表的关于盐酸阿比多尔对比其他抗病毒药物治疗中国人群呼吸道病毒感染的随机对照试验(randomized controlled trial,RCT),检索时限均从建库至2020年2月20日。由2名研究者独立进行文献筛选、资料提取及偏倚风险评价。采用RevMan 5.3软件进行Meta分析。结果最终纳入6篇RCT文献,共883例呼吸道病毒感染患者,其中493例给予盐酸阿比多尔(观察组),390例给予利巴韦林(对照组)。Meta分析结果显示:当疗程≤5 d时,盐酸阿比多尔治疗成人呼吸道病毒感染的总有效率(RR=1.21,95%CI:1.08~1.36,P=0.0008)和痊愈率(RR=1.43,95%CI:1.08~1.88,P=0.01)优于利巴韦林;当疗程>5 d时,2组总有效率(RR=1.06,95%CI:0.95~1.19,P=0.29)和痊愈率(RR=1.10,95%CI:0.98~1.23,P=0.12)差异无统计学意义。盐酸阿比多尔对比利巴韦林治疗成人呼吸道病毒感染的不良反应发生率差异无统计学意义(RR=0.71,95%CI:0.41~1.24,P=0.23)。结论基于目前临床证据,盐酸阿比多尔治疗中国成人呼吸道病毒感染安全有效。但由于纳入研究质量和数量的限制,仍需要更多高质量和大样本的研究进行验证。Objective To systematically review the efficacy and safety of arbidol hydrochloride for respiratory viral infection in Chinese population. Methods Randomized controlled trials(RCTs)of arbidol hydrochloride compared with other antiviral drugs in the treatment of respiratory viral infection were searched in Embase,PubMed,Cochrane Library,CNKI,Wanfang and VIP databases. The publication dates ranged from the origin of the databases to February 20 th,2020. Literature screening data extraction and risk assessment for bias were independently performed by two reviewers. Meta-analysis was done by RevMan 5. 3 software. Results 6 RCTs were included,involving 883 patients,of which 493 were treated with arbidol hydrochloride(the observation group),the others were treated with ribavirin(the control group). Meta-analysis showed that when the course of treatment was less than 5 days,the total effective rate(RR=1. 21,95%CI:1. 08-1. 36,P=0. 0008)and the cure rate(RR=1. 43,95%CI:1. 08-1. 88,P=0. 01)of arbidol hydrochloride in the treatment of adult respiratory viral infection were superior to those of the ribavirin group;when the course of treatment was more than 5 days,there were no significant differences in the total effective rate(RR=1. 06,95%CI:0. 95-1. 19,P=0. 29)and the cure rate(RR=1. 10,95%CI:0. 98-1. 23,P=0. 12)in two groups. There was no significant difference in the incidence of adverse reactions between the arbidol group and the ribavirin group(RR=0. 71,95%CI:0. 41-1. 24,P=0. 23). Conclusion According to the current clinical evidence,arbidol hydrochloride is effective and safe for the treatment of Chinese adults with respiratory viral infection. Due to the limitations of the quality and quantity of the included studies,this conclusion needs more high-quality and large sample size trials to be confirmed.

关 键 词：阿比多尔 呼吸道病毒感染 系统评价 META分析 随机对照试验 

分 类 号：R511[医药卫生—内科学] R978.7[医药卫生—临床医学]